Compare DAC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | PHVS |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | Greece | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2006 | 2020 |
| Metric | DAC | PHVS |
|---|---|---|
| Price | $117.30 | $28.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $112.50 | $41.82 |
| AVG Volume (30 Days) | 51.6K | ★ 214.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $79.48 | $15.51 |
| 52 Week High | $120.00 | $30.24 |
| Indicator | DAC | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.86 | 52.14 |
| Support Level | $91.64 | $24.55 |
| Resistance Level | $118.58 | $29.82 |
| Average True Range (ATR) | 2.73 | 1.42 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 61.77 | 56.08 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.